CL2008001848A1 - Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal. - Google Patents

Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal.

Info

Publication number
CL2008001848A1
CL2008001848A1 CL2008001848A CL2008001848A CL2008001848A1 CL 2008001848 A1 CL2008001848 A1 CL 2008001848A1 CL 2008001848 A CL2008001848 A CL 2008001848A CL 2008001848 A CL2008001848 A CL 2008001848A CL 2008001848 A1 CL2008001848 A1 CL 2008001848A1
Authority
CL
Chile
Prior art keywords
benzodiazepine
combination
chemotherapeutic agent
peeeeeeeequenas
imidazolo
Prior art date
Application number
CL2008001848A
Other languages
English (en)
Spanish (es)
Inventor
Aburub Aktham
Chedid Marcio
Albert Engler Thomas
Vasudevan Venkatraghavan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001848(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2008001848A1 publication Critical patent/CL2008001848A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2008001848A 2007-07-02 2008-06-20 Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal. CL2008001848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02

Publications (1)

Publication Number Publication Date
CL2008001848A1 true CL2008001848A1 (es) 2009-05-29

Family

ID=39737054

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2008001848A CL2008001848A1 (es) 2007-07-02 2008-06-20 Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal.
CL2011003046A CL2011003046A1 (es) 2007-07-02 2011-12-02 Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2011003046A CL2011003046A1 (es) 2007-07-02 2011-12-02 Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08).

Country Status (22)

Country Link
US (2) US8318713B2 (enExample)
EP (1) EP2173348B1 (enExample)
JP (2) JP5551589B2 (enExample)
KR (1) KR101230085B1 (enExample)
CN (2) CN102772416A (enExample)
AR (1) AR067112A1 (enExample)
AU (1) AU2008270732B2 (enExample)
BR (1) BRPI0813789A2 (enExample)
CA (1) CA2691587C (enExample)
CL (2) CL2008001848A1 (enExample)
EA (2) EA023697B1 (enExample)
ES (1) ES2561202T3 (enExample)
IL (2) IL202237A (enExample)
MA (1) MA31677B1 (enExample)
MX (1) MX2009013449A (enExample)
MY (1) MY154472A (enExample)
NZ (1) NZ581355A (enExample)
PE (1) PE20090838A1 (enExample)
TW (1) TWI428132B (enExample)
UA (1) UA97400C2 (enExample)
WO (1) WO2009006043A2 (enExample)
ZA (1) ZA200908725B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
US8802668B2 (en) 2009-04-14 2014-08-12 Eli Lilly And Company Hematopoietic neoplasm chemotherapy
JP2014531456A (ja) * 2011-09-22 2014-11-27 バインド セラピューティックス インコーポレイテッド 治療用ナノ粒子と癌を治療する方法
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Gsk3阻害剤と抗dr5抗体の組み合わせ
CN107613983B (zh) * 2015-04-30 2021-05-04 大鹏药品工业株式会社 抗肿瘤剂的副作用减轻剂
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CN110392686A (zh) * 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びwnt作動薬
CA3222225A1 (en) * 2021-06-03 2022-12-08 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
KR100974770B1 (ko) * 2002-03-05 2010-08-06 일라이 릴리 앤드 캄파니 키나제 억제제로서의 퓨린 유도체
CA2499639C (en) * 2002-09-19 2011-11-08 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
US20110293746A1 (en) * 2004-07-09 2011-12-01 Agency For Science, Technology And Research Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US20060252082A1 (en) * 2005-05-04 2006-11-09 University Of South Florida Predicting treatment response in cancer subjects
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Also Published As

Publication number Publication date
UA97400C2 (uk) 2012-02-10
US20130039996A1 (en) 2013-02-14
EP2173348A2 (en) 2010-04-14
US20100166884A1 (en) 2010-07-01
ES2561202T3 (es) 2016-02-25
CA2691587C (en) 2013-09-24
CN102772416A (zh) 2012-11-14
JP2010532364A (ja) 2010-10-07
IL218443A0 (en) 2012-04-30
AU2008270732A1 (en) 2009-01-08
US8648063B2 (en) 2014-02-11
EA201201155A1 (ru) 2014-11-28
KR101230085B1 (ko) 2013-02-05
BRPI0813789A2 (pt) 2014-12-30
ZA200908725B (en) 2011-02-23
JP5551589B2 (ja) 2014-07-16
PE20090838A1 (es) 2009-07-02
CA2691587A1 (en) 2009-01-08
EA023697B1 (ru) 2016-07-29
MY154472A (en) 2015-06-30
EA201070085A1 (ru) 2010-04-30
CL2011003046A1 (es) 2012-08-24
IL202237A (en) 2014-05-28
TW200911272A (en) 2009-03-16
CN101743005B (zh) 2013-06-12
MA31677B1 (fr) 2010-09-01
KR20100017984A (ko) 2010-02-16
WO2009006043A2 (en) 2009-01-08
HK1141236A1 (zh) 2010-11-05
TWI428132B (zh) 2014-03-01
MX2009013449A (es) 2010-01-15
NZ581355A (en) 2012-04-27
US8318713B2 (en) 2012-11-27
CN101743005A (zh) 2010-06-16
AU2008270732B2 (en) 2013-01-31
WO2009006043A3 (en) 2009-04-16
IL202237A0 (en) 2010-06-16
AR067112A1 (es) 2009-09-30
EP2173348B1 (en) 2015-12-09
JP2014114297A (ja) 2014-06-26
EA018447B1 (ru) 2013-08-30

Similar Documents

Publication Publication Date Title
CL2008001848A1 (es) Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal.
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
ECSP088425A (es) INHIBIDORES DE LA ACTIVIDAD Akt
JP2010532364A5 (enExample)
MX2011010937A (es) Derivado benzodiazepina para el tratamiento de neoplasma hermatopoyetico y leucemia.
WO2009139921A3 (en) Microorganisms for preventing and treating neoplasms accompanying cellular therapy
NZ611964A (en) Bromodomain inhibitors and uses thereof
CL2008002139A1 (es) Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer.
CL2008002687A1 (es) Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
PH12013500742A1 (en) Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
NZ751509A (en) Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
IL214348A (en) Use of (-) - trans – 3– (6,5 – dihydro-h4 – pyrrolo [1,2,3 ji] quinoline – 1 – il) –4– (h1– indole – 3 – il) –pyrrolidine – 5, 2 - Deion for the preparation of a drug for the treatment of cancer that is suitable for use with sorfiniv or arlotinib
AR082691A1 (es) Terapia de combinacion, producto farmaceutico, kit y uso
WO2021080920A3 (en) Combination therapy for the treatment of solid and hematological cancers
EP2277884A8 (en) Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
CL2007001795A1 (es) Compuestos derivados de 4-oxo-1,2,8-triaza-espiro[4.5] decano, que actuan como inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y uso de los compuestos en la prepararcion de medicamentos para tratar o prevenir arritmias cardiacas
WO2006113837A3 (en) Inhibitors of akt activity
WO2022221834A3 (en) Method for treating lung cancer and non-small cell lung cancer
HRP20110360T1 (hr) Kombinacija zd6474 i pemetrekseda